Hideo Tomioka

Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks

Yu Kataoka, Toru Mukohara, Hideo Tomioka et al. · Investigational New Drugs · 2011 · 118 citations

Tumor Biology, Radiation Oncology, Signaling Pathway +8

Involvement of herbal medicine as a cause of mesenteric phlebosclerosis: results from a large-scale nationwide survey

Seiji Shimizu, Taku Kobayashi, Hideo Tomioka et al. · Journal of Gastroenterology · 2016 · 49 citations

Large-scale Nationwide Survey, Traditional Medicine, Cardiovascular Disease +10

TYRO3 as a potential therapeutic target in breast cancer.

Roudy Chiminch Ekyalongo, Toru Mukohara, Yohei Funakoshi et al. · PubMed · 2014 · 32 citations

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin

Yohei Funakoshi, Yutaka Fujiwara, Naomi Kiyota et al. · Cancer Chemotherapy and Pharmacology · 2016 · 29 citations · Full text

Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification

Hideo Tomioka, Toru Mukohara, Yu Kataoka et al. · International Journal of Oncology · 2012 · 27 citations · Full text

Fluorouracil-induced Apoptosis, Apoptosis, Cell Death +16